GAMMA Investing LLC Purchases 135,286 Shares of argenx SE (NASDAQ:ARGX)

GAMMA Investing LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 53,684.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 135,538 shares of the company's stock after purchasing an additional 135,286 shares during the quarter. GAMMA Investing LLC owned about 0.22% of argenx worth $802,200,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its position in argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares during the last quarter. Capital World Investors grew its holdings in shares of argenx by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after buying an additional 86,687 shares during the period. RTW Investments LP lifted its position in argenx by 2.9% in the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after acquiring an additional 19,067 shares in the last quarter. Clearbridge Investments LLC lifted its position in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after buying an additional 40,330 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock worth $185,821,000 after buying an additional 64,183 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 0.6%

ARGX stock traded down $3.62 during midday trading on Tuesday, hitting $580.99. 114,838 shares of the company's stock were exchanged, compared to its average volume of 322,466. The stock has a market capitalization of $35.48 billion, a price-to-earnings ratio of -660.22 and a beta of 0.57. The firm has a 50 day moving average price of $586.59 and a 200-day moving average price of $612.78. argenx SE has a 12-month low of $368.57 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, sell-side analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ARGX. Wells Fargo & Company increased their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Guggenheim dropped their price objective on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Baird R W upgraded shares of argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Citigroup reaffirmed a "buy" rating on shares of argenx in a research report on Wednesday, May 21st. Finally, Oppenheimer upped their price target on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $709.18.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.